Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,256 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Triptans Clear all

Conditions: Leukemia, Lymphoma
Interventions: filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, methotrexate, vincristine sulfate; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 12
States / cities: Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 9 more

Conditions: Lymphoma, Hodgkin Disease, Lymphoma, Hodgkin Disease, Lymphoma: Hodgkin
Interventions: Vincristine, Cyclophosphamide, Doxorubicin, Prednisone, Bleomycin, Etoposide, Low-dose radiotherapy (RT); Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 2
States / cities: Stanford, California • Vallejo, California

Conditions: Obesity, Prediabetic State
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Medulloblastoma
Interventions: Cisplatin, Craniospinal Irradiation, Cyclophosphamide, Involved-Field Radiation Therapy, Laboratory Biomarker Analysis, Lomustine, Quality-of-Life Assessment, Radiation Therapy, Vincristine Sulfate; Drug · Radiation · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2024
U.S. locations: 174
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more

Conditions: B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Interventions: nilotinib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, methotrexate, cytarabine, prednisone, mesna, dexamethasone, leucovorin calcium; Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Leukemia, Myelocytic, Acute
Interventions: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 8
States / cities: Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, vinorelbine ditartrate; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Phase I
Interventions: Psilocybin (Usona Institute), Inactive Placebo (Usona Institute); Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Postoperative Pain, Delirium, Confusion, Sleep
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Follicular Lymphoma (FL)
Interventions: Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 58
States / cities: Fresno, California • San Diego, California • Santa Barbara, California + 48 more

Conditions: Improving Cardiometabolic Outcomes in Adults
Interventions: Melatonin 1 mg, Placebos, Meal Timing, NON Meal Timing; Dietary Supplement · Other
Lead sponsor: Northwestern University; Other
Eligibility: 35 Years to 54 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Treatment Resistant Depression
Interventions: Psilocybin; Drug
Lead sponsor: Sheppard Pratt Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Palo Alto, California • Baltimore, Maryland

Conditions: Healthy
Interventions: Yohimbine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Interventions: Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 39 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Dallas, Texas

Conditions: Intraocular Retinoblastoma
Interventions: liposomal vincristine sulfate, cryosurgery, laser surgery, carboplatin, etoposide, filgrastim; Drug · Procedure · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 11
States / cities: Arcadia, California • Downey, California • Los Angeles, California + 7 more

Conditions: Recurrent Melanoma, Stage IV Skin Melanoma
Interventions: Cisplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Vinblastine Sulfate; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Placebo, Psilocybin 15mg; Drug
Lead sponsor: Manoj Doss; Other
Eligibility: 21 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: sargramostim, cyclophosphamide, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 16 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ganglioneuroblastoma, High Risk Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, External Beam Radiation Therapy, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Vinorelbine Tartrate; Drug · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 70 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 5
States / cities: Grand Island, Nebraska • North Platte, Nebraska • Omaha, Nebraska + 1 more

Conditions: Cancer
Interventions: Multivitamin (MV), Multivitamin + Vitamin B12 + Vitamin B6, Chemotherapy; Dietary Supplement · Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 5
States / cities: Albuquerque, New Mexico • Santa Fe, New Mexico

Conditions: Bladder Cancer
Interventions: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 566
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 342 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Lymphoblastic Leukemia
Interventions: Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

Effect of Melatonin on Cardiometabolic Risk- FULL

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation

Study of Melatonin on Sleep, Pain, and Confusion After Joint Replacement Surgery

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Strengthening Circadian Signals

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Effects of Stress Hormones on Emotion and Cognition

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function

Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer

A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Intensified Post Remission Therapy Containing PEG-Asparaginase